Galapagos and NovAliX enter into an integrated drug discovery collaboration
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery…
News
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
– Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with…
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b…
IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months…
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
Fortress expects to file a total of three new drug applications in 2023 Record consolidated…
PROCEPT BioRobotics Corp. Announces Investor Event at 2023 AUA Annual Meeting in Chicago
REDWOOD CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”),…
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May…
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., March 30,…
Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update
Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line…
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line Image: GreenLight Biosciences…
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
– Full enrollment of the LUNA trial anticipated in the second half of 2023 –…
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and…
IGM Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
– Encouraging initial data from IGM-8444 combination with FOLFIRI; first patient dosed in randomized trial…
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations
DOYLESTOWN, Pa., March 30, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
MIAMI, March 30, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the…
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target…
Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Positive topline results from single and multiple ascending dose parts of the Phase 1 study…
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
A clinical trial generating safety, pharmacokinetics, and dosing data with the goal of providing information…
Nkarta Announces Departure of Chief Financial & Business Officer
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full…
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71%…